Literature DB >> 11583306

Thrombophilic risk factors in patients with central retinal vein occlusion.

R Marcucci1, L Bertini, B Giusti, T Brunelli, S Fedi, A P Cellai, D Poli, G Pepe, R Abbate, D Prisco.   

Abstract

Few and contrasting data are available on the prevalence of hemostatic risk factors in patients with central retinal vein occlusion (CRVO). Aim of this study was to investigate the metabolic and inherited risk factors for venous thrombosis in 100 CRVO patients (age: 59 yrs; range 18-77) and in 100 controls (age: 56 yrs; range 18-84). In patients homocysteine (Hcy) levels were significantly higher than in controls and were affected by the C677T methylenetetrahydrofolate reductase (MTHFR) polymorphism (p < 0.001). The prevalences of activated protein C resistance (APCR), factor V Leiden positivity, elevated PAI-1 and Lp(a) levels were significantly higher in patients with respect to controls. At multivariate analysis, only hyperhomocysteinemia (OR 11, 95% CI 3.6-36.2; p < 0.0001) and elevated PAI-1 levels (OR 8.9, 95% CI 3.5-41.3; p < 0.01), in addition to hypertension (OR 40.5, 95% CI 8.6-188.8; p < 0.00001) and hypercholesterolemia (OR 3.1, 95% CI 1.6-20.5; p < 0.05), were independent risk factors for CRVO. These data demonstrate a potential role of hemostatic risk factors in the pathophysiology of CRVO.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11583306

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  15 in total

1.  [Multiple thrombophilic risk markers in patients ≺65 years of age with retinal vein occlusion].

Authors:  C Kuhli-Hattenbach; P Hellstern; W Miesbach; T Kohnen; L-O Hattenbach
Journal:  Ophthalmologe       Date:  2017-12       Impact factor: 1.059

2.  Homocysteine levels in aqueous humor and plasma of patients with primary open-angle glaucoma.

Authors:  J B Roedl; S Bleich; U Reulbach; N von Ahsen; U Schlötzer-Schrehardt; R Rejdak; G O H Naumann; F E Kruse; J Kornhuber; A G M Jünemann
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

3.  Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion.

Authors:  Marianne L Shahsuvaryan
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

4.  Retinal vein occlusion: evaluation of "classic" and "emerging" risk factors and treatment.

Authors:  Marina Turello; Samantha Pasca; Roberto Daminato; Patrizia Dello Russo; Roberta Giacomello; Ugo Venturelli; Giovanni Barillari
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

Review 5.  Retinal vein occlusions: a review for the internist.

Authors:  Rossella Marcucci; Francesco Sofi; Elisa Grifoni; Andrea Sodi; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2010-12-14       Impact factor: 3.397

6.  Cardiovascular risk factors and outcome in patients with retinal vein occlusion.

Authors:  Mirko Di Capua; Antonio Coppola; Rosina Albisinni; Antonella Tufano; Anna Guida; Matteo Nicola Dario Di Minno; Ferdinando Cirillo; Marcello Loffredo; Anna Maria Cerbone
Journal:  J Thromb Thrombolysis       Date:  2010-07       Impact factor: 2.300

Review 7.  [Antiphospholipid syndrome and retinal vein occlusion. Meta-analysis of Published Studies].

Authors:  M Rehak; M Müller; M Scholz; J Wiercinska; D Niederwieser; P Wiedemann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

8.  A longitudinal analysis of risk factors associated with central retinal vein occlusion.

Authors:  Maxwell S Stem; Nidhi Talwar; Grant M Comer; Joshua D Stein
Journal:  Ophthalmology       Date:  2012-11-20       Impact factor: 12.079

9.  Presumed bilateral branch retinal vein occlusions secondary to antiepileptic agents.

Authors:  Rumana N Hussain; Somnath Banerjee
Journal:  Clin Ophthalmol       Date:  2011-05-13

Review 10.  Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities.

Authors:  Jiri Rehak; Matus Rehak
Journal:  Curr Eye Res       Date:  2008-02       Impact factor: 2.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.